tbuckley/cabot-search huggingface dataset:
EXPOSURE OF QUACKERY DOING GOOD.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Figure
Authors: Zhenqiu Lin, Shu-Xia Li, Finlay Mcalister
Journal: JAMA Cardiology (2019)

Valerie D. Myers, MS; Glenn S. Gerhard, MD; Dennis M. McNamara, MD; Dhanendra Tomar, PhD; Muniswamy Madesh, PhD; Scott Kaniper, BS; Frederick V. Ramsey, PhD; Susan G. Fisher, PhD; Roxann G. Ingersoll, MHS; Laura Kasch-Semenza, BA; JuFang Wang, MD; Karen Hanley-Yanez, BS; Bonnie Lemster, MPH; Jessica A. Schwisow, BS; Amrut V. Ambardekar, MD; Seta H. Degann, MS; Michael R. Bristow, MD, PhD; Richard Sheppard, MD; Jeffrey D. Alexis, MD; Douglas G. Tilley, PhD; Christopher D. Kontos, MD; Joseph M. McClung, PhD; Anne L. Taylor, MD; Clyde W. Yancy, MD, MSc; Kamel Khalili, PhD; Jonathan G. Seidman, PhD; Christine E. Seidman, MD; Charles F. McTiernan, PhD; Joseph Y. Cheung, MD, PhD; Arthur M. Feldman, MD, PhD
Carcinogenicity of Lipid-Lowering Drugs
Authors: Marco Pahor
Journal: JAMA (1996)

<h3>To the Editor.</h3> —In their article, Drs Newman and Hulley<sup>1</sup>reviewed available data about potential carcinogenicity of lipid-lowering drugs and concluded that "most cholesterol-lowering drugs cause or promote cancer in rodents" and "[u]se of cholesterol-lowering drugs should be restricted to those at high risk of short-term CHD death." The authors addressed the issue only partially and failed to report the alternative view that statins may instead protect against cancer. There is emerging evidence that the HMG-CoA reductase inhibitor lovastatin can induce apoptosis in vitro in various cell lines, including tumor cells.<sup>2,3</sup>Such an effect was dose dependent and was observed at low doses (100 nmol/L). The suspected carcinogenic effects are likely to occur at much higher concentrations. Apoptosis or genetically programmed cell death is an efficient mechanism for eliminating cancer cells and, therefore, for aborting cancer growth.<sup>4</sup>Anticancer drugs act mainly by inducing apoptosis, and HMG-CoA reductase
Familial Dysautonomia
Authors: Joseph Dancis, Alfred A. Smith
Journal: New England Journal of Medicine (1966)

FAMILIAL dysautonomia was established as a clinical entity in 1949.1 The early reports clearly describe the unusual constellation of symptoms, which ordinarily make the diagnosis relatively simple.2 It typically involves a Jewish child with a history of dysphagia and recurrent bronchopneumonia as an infant. Later, an absence of tears, poor motor co-ordination, postural hypotension, emotional lability, with hypertensive episodes, vomiting, skin blotching and excessive perspiration, are noted. Autopsy reports2 3 4 have not been consistent, suggesting that the observations may not be fundamental to the disease.In recent years efforts have been directed toward investigating the abnormal physiology. Some of the observations . . .
Consultant Crisis
Authors: D. H. Teasdale, M. G. Nott, I. G. Schraibman, I. B. Munro, G. F. W. Hossack, J. Lendrum, J. P. Fraser, V. D. Dalal, L. W. Purnell, J. T. Elliott, S. Falk, J. A. Shrigley, A. K. Maude, J. McLenachan, J. L. Taylor, D. Walton, J. M. Main, A. Higham, D. Procter, M. Ahmed, M. A. Cheema
Journal: BMJ (1974)
Cardiopulmonary Arrest
Authors: Alan H. Goldberg
Journal: New England Journal of Medicine (1974)

CARDIOPULMONARY arrest is the absence of functional ventilation and circulation in a person who is not expected to die. This includes patients with life-threatening but reversible aberrations of cardiopulmonary function as may be seen in coronary occlusion, asphyxia (drowning, carbon monoxide, drug overdose or fires), anaphylactic reactions (to medications, insects or foods) and electrocution (electricity or lightning).DiagnosisThe absence of functional ventilation is determined by the lack of any abdominal or thoracic movements, and the absence of breath sounds or movements through the mouth and nose. Occasionally, movements of the chest and abdomen will occur, unaccompanied by any air motion at . . .
Medical ethics
Authors: R. M. Veatch
Journal: JAMA (1979)

In the field of medical ethics, a year is such a thin sliver of time that the events capturing attention are to some extent accidents of history. Medical ethics, like the more general problems of ethics (of which it is a part), is best perceived from a perspective of centuries rather than months. Even so, several events of the past year have been of compelling interest to people concerned with problems of ethics in medicine. These issues have pressed themselves alike on scholars working in the field, on clinicians struggling with decisions in their daily practice, on administrators in professional and government organizations, and on people trying to be responsible patients. <h3>Decisions for Incompetent Patients</h3> Late in 1977 the Massachusetts Supreme Court issued a written opinion explaining why it had intervened to order physicians to stop treating Joseph Saikewicz.<sup>1</sup>Saikewicz was a 67-year-old man suffering from acute myeloblastic monocytic
Dr. Joseph Alexander Parker is Not Dead.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinicopathological features of patients with malignant mesothelioma in a multicenter, retrospective study.
Authors: Manlio Mencoboni, Rosa Filiberti, Lisette DelCorso, Andrea Bruzzone, Federica Grosso, Giulia Pasello, Adolfo G. Favaretto, Hector J. Soto Parra, Paola Taveggia, Matteo Perrino, Paolo Andrea Zucali, Giovanni Luca Ceresoli
Journal: Journal of Clinical Oncology (2015)

e12651 Background: survival of patients with pleural mesothelioma is generally poor. We retrospectively evaluated clinical data and survival of mesothelioma patients who were treated in 6 Centers in Italy. Methods: 358 pts were included.The association between prognostic factors and survival was analyzed in univariate and multivariate analyses Results: median age was 69.6 (range 36-94) and 74% of patients were male.PS was 0-1 in 94%, 2 or more in 3%.Epithelioid (79%) was the most common histology.Surgery was performed in 23% of pts. Radiotherapy was performed in 37%; 7% of patients underwent trimodality treatment. First line chemotherapy was administered to 99% and pemetrexed-based chemotherapy was administered to 68% of pts. Overall median survival was 19.1 months (95%CI 16.6-21.6). 18% of pts survived > 36 months. Factors significantly associated with survival in univariate analysis were age (younger better, p < 0.001; < = 7034.5 vs 15.4), PS (0-1 better, p 0.005; 19*.6 vs 7.4), surgery (p < 0.001; 38.3 vs 15.9), radiotherapy (p < 0.001; 27.6 vs 15.8), histology (epithelioid better, p < 0.001; 21.6 vs 10.1 sarcomatous/mixed), best response at first line chemotherapy (p < 0.001; 10.3 P vs 24.5 SD vs 25.0 R). Multivariate analysis confirmed the independent role of surgery (surgery better: HR = 0.61, 95%CI 0.51-0.72, p < 0.001), morphology (sarcomatoid/mixed worse HR = 1.40, 95%CI 1.16-1.69, p < 0.001), PS ( > = 2 vs 0-1,HR = 1.45, 95%CI 1.01-2.10, p = 0.046, best response (PD vs SD/R = 1.86, 95% CI 1.58-2.20, p < 0.001).Compared to the other pts, more 3-year survivors were younger (p = 0.008) and had more radiotherapy (p = 0.005) and surgery (p < 0.001). Conclusions: surgery, epithelioid histology, low PS and response to therapy were favorable prognostic factors in our mesothelioma patients.
Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study
Authors: Aminah Jatoi, Harold E. Windschitl, Charles L. Loprinzi, Jeff A. Sloan, Shaker R. Dakhil, James A. Mailliard, Sarode Pundaleeka, Carl G. Kardinal, Tom R. Fitch, James E. Krook, Paul J. Novotny, Brad Christensen
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia. PATIENTS AND METHODS: Four hundred sixty-nine assessable advanced cancer patients were randomized to (1) oral megestrol acetate 800 mg/d liquid suspension plus placebo, (2) oral dronabinol 2.5 mg twice a day plus placebo, or (3) both agents. Eligible patients acknowledged that loss of appetite or weight was a problem and reported the loss of 5 pounds or more during 2 months and/or a daily intake of less than 20 calories/kg of body weight. RESULTS: Groups were comparable at baseline in age, sex, tumor type, weight loss, and performance status. A greater percentage of megestrol acetate-treated patients reported appetite improvement and weight gain compared with dronabinol-treated patients: 75% versus 49% (P = .0001) for appetite and 11% versus 3% (P = .02) for ≥ 10% baseline weight gain. Combination treatment resulted in no significant differences in appetite or weight compared with megestrol acetate alone. The Functional Assessment of Anorexia/Cachexia Therapy questionnaire, which emphasizes anorexia-related questions, demonstrated an improvement in quality of life (QOL) among megestrol acetate–treated and combination-treated patients. The single-item Uniscale, a global QOL instrument, found comparable scores. Toxicity was also comparable, with the exception of an increased incidence of impotence among men who received megestrol acetate. CONCLUSION: In the doses and schedules we studied, megestrol acetate provided superior anorexia palliation among advanced cancer patients compared with dronabinol alone. Combination therapy did not appear to confer additional benefit.
Trees and CO <sub>2</sub>
Journal: Environmental Health Perspectives (1996)

Thirsty PlanetThe world is experiencing a major water cri- sis that will continue to worsen unless cur- rent conditions change, says the World Bank.An August World Bank report stated that 30 countries containing 40% of the world's population are already experiencing water shortages that threaten their agricul- ture, industry, and health.According to the report, population growth and contamination of water are the major causes of these water shortages.The report was prepared for the World Bank's fifth annual water symposium, which was held August 13-18 in Stockholm.In presenting the report at the conference, Ismail Serageldin, vice president of the World Bank, said, "The water problem in most countries stems not from a shortage ofwater, but rather mainly from inefficient and unsustainable use of water resources, a situation that cannot continue."The report states that most of the countries experiencing water shortages are in areas where populations are growing quickly, such as the Middle East, North Africa, Central Asia, and sub-Saharan Africa.Other areas facing water shortages include northern China, western and southern India, western South America, Pakistan, and Mexico.Pollution is also a large problem affecting water in Eastern Europe.
VARIABILITY IN CRUDE PRODUCTS CONTAINING ALKALOIDS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Breast Cancer
Authors: Daniella Duke
Journal: Annals of Internal Medicine (1993)

Ad Libitum1 May 1993Breast CancerDaniella Duke, MDDaniella Duke, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-9-199305010-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail frightened ... Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1993Volume 118, Issue 9Page: 745KeywordsBoneBreast cancerComputed axial tomographyDrugsNauseaScarsThorax ePublished: 15 August 2000 Issue Published: 1 May 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Table of Contents
Authors: Jorge Kizer, Susann Blüher, Peter Schwarz, Takahiro Kuwashiro, Tetsuro Ago, Masahiro Kamouchi, Ryu Matsuo, Jun Hata, Junya Kuroda, Kenji Fukuda, Hiroshi Sugimori, Masayo Fukuhara, Hideto Awano, Tetsu Isomura, Kazuo Suzuki, Masahiro Yasaka, Yasushi Okada, Yutaka Kiyohara, Takanari Kitazono, Julian Sacre, Christine Jellis, Carly Jenkins, Brian Haluska, Mathias Baumert, Jeff Coombes, Thomas Marwick
Journal: Metabolism (2014)
Retraction Note: Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between the NPM leukemic mutant and NF-κB in AML carrying NPM1 mutations
Authors: D Cilloni, F Messa, V Rosso, F Arruga, I Defilippi, S Carturan, R Catalano, M Pautasso, C Panuzzo, P Nicoli, E Messa, A Morotti, I Iacobucci, G Martinelli, E Bracco, G Saglio
Journal: Leukemia (2010)
On Testing the Sense of Smell
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editorial: Heat as cancer therapy
Authors: J. M. Bull
Journal: JAMA (1976)

Recent clinical reports of hyperthermic tumor regression revitalize an old interest in heat as an anticancer therapy. The clinical observations are supported by experimental data demonstrating that hyperthermia as a single modality kills tumor cells in animal models and in vitro. While the mechanism of injury is imperfectly understood, it is clear that heat induces selective lethal injury to malignant cells, and that this effect is critically dependent on temperature and time of heat exposure. Giovanella et al<sup>1</sup>found that temperatures from 37 to 40 C had little effect on the viability and subsequent ability to metastasize of L1210 leukemia cells, whereas temperatures higher than 41 C killed the tumor cells. Palzer and Heidelberger<sup>2</sup>further defined a critical temperature-time relationship in the 41.0 to 43.0 C temperature range using HeLa cells. Overgaard and Overgaard<sup>3</sup>showed that temperatures of 41.5 to 43.5 C destroyed mouse mammary-tumor implants without
APPENDICITIS.
Authors: JOSEPH PRICE
Journal: JAMA (1900)

For a number of years my experience differed from that of many operators in the fact that the trouble occurred 16 in the male to 1 in the female. An operation on a female, young or old, was uncommon; in boys and young men, very common. In the work of Hunter McGuire the proportion was precisely the same. In the last three years my experience has wonderfully changed—the proportion now is about the same. Coincident with increasing numbers of young females, I had a group of old women—some five or six, 60 to 72 years old—with severe attacks of appendicitis, most of them gangrenous. In young women and children it has occurred in working girls and in young women fond of field sports. This has also been so in young men, about all of them have followed trades or some professional sport. It is simply surprising the great number of